PPARδ comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-03-16. Numbers and descriptions here follow the published literature rather than marketing material.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ | Nuclear receptor; not androgen receptor |
| Studied indications | Dyslipidemia; obesity; diabetes | Early clinical research; development discontinued |
| Rodent toxicity | Tumor formation in multiple tissues | Dose-dependent findings in some studies |
| Human approval | None | No approved therapeutic use |
| Typical analytical method | LC-MS/MS | Used for identity and quantification |
A variety of natural and synthetic inhibitors of ATP synthase have been discovered. These have been used to probe the structure and mechanism of ATP synthase. Some may be of therapeutic use. There are several classes of ATP synthase inhibitors, including peptide inhibitors, polyphenolic phytochemicals, polyketides, organotin compounds, polyenic α-pyrone derivatives, cationic inhibitors, substrate analogs, amino acid modifiers, and other miscellaneous chemicals. Some of the most commonly used ATP synthase inhibitors are oligomycin and DCCD. E. coli ATP synthase is the simplest known form of ATP synthase, with 8 different subunit types. Bacterial F-ATPases can occasionally operate in reverse, turning them into an ATPase. Some bacteria have no F-ATPase, using an A/V-type ATPase bidirectionally. Yeast ATP synthase is one of the best-studied eukaryotic ATP synthases; and five F1, eight FO subunits, and seven associated proteins have been identified. Most of these proteins have homologues in other eukaryotes.
Sunflower trypsin inhibitor (SFTI) is a small, circular peptide produced in sunflower seeds, and is a potent inhibitor of trypsin. It is the smallest known member of the Bowman-Birk family of serine protease inhibitors. One example of Sunflower trypsin inhibitor is Sunflower trypsin inhibitor-1 (SFTI-1). Sunflower trypsin inhibitor-1 is a potent Bowman-Birk inhibitor. Sunflower trypsin inhibitor-1 is the simplest cysteine-rich peptide scaffold because it is a bicyclic 14 amino acid peptide and only has one disulfide bond. The disulfide bond divides the peptide into a primary trypsin inhibitory loop (Thr4-Ile10) and a cyclisation loop (Phe12-Arg2). The cyclisation loop can be replaced by a foregin bioactive loop without disrupting the scaffold's fold. It is extracted from a seed of a sunflower called Helianthus annuus. The synthesis of SFTI is not known however, it can evolutionarily linked to a gene-coded product from classic Bowman-Birk inhibitors. STFI is used in radiopharmaceutical, antimicrobial, and pro-angiogenic peptides.
Multiple studies done both in and outside India have shown an increased prevalence of pseudocholinesterase deficiency amongst the Arya Vysya community. A study performed in the Indian state of Tamil Nadu in Coimbatore on 22 men and women from this community showed that 9 of them had butyrylcholinesterase deficiency, which translates to a prevalence that is 4000-fold higher than that in European and American populations. Butyrylcholinesterase deficiency is common within the Persian and Iraqi Jewish populations. Approximately one in 10 Persian Jews are known to have a mutation in the gene causing this disorder and thus one in 100 couples will both carry the mutant gene and each of their children will have a 25% chance of having two mutant genes, and thus be affected with this disorder. This means that one out of 400 Persian Jews is affected with this condition. Cholinesterase Test - Lab Tests Online
Pyocyanin inactivates catalase by reducing its gene’s transcription as well as directly targeting the enzyme itself. Glutathione is an important antioxidant modulated by pyocyanin. In particular the pool of the reduced form is depleted while the oxidised form is promoted by hydrogen peroxide which is not dismutated by catalase. In the cystic fibrosis lung, intracellular pyocyanin converts molecular oxygen to the superoxide free radical by oxidizing NADPH to NADP+. This has a doubly negative effect on the lungs. Firstly, the NADPH used by pyocyanin depletes the available substrate for the reaction catalysed by the NADPH oxidase enzyme. Secondly, the superoxide radical generated can inhibit cytokines, such as IL-4, IL-13 and IFN-γ, which usually upregulate NADPH oxidase. When the lung is confronted with pyocyanin, an increased concentration of catalase and superoxide dismutase is seen in order to deal with the barrage of radicals being produced.
Lutetium is a chemical element; it has symbol Lu and atomic number 71. It is a silvery white metal which resists corrosion in dry air, but not in moist air. Lutetium is the last element in the lanthanide series, and it is traditionally counted among the rare earth elements; it can also be classified as the first element of the sixth-period transition metals. Lutetium was independently discovered in 1907 by French scientist Georges Urbain, Austrian mineralogist Baron Carl Auer von Welsbach, and American chemist Charles James. All of these researchers found lutetium as an impurity in ytterbium. The dispute on the priority of the discovery occurred shortly after, with Urbain and Welsbach accusing each other of publishing results influenced by the published research of the other; the naming honor went to Urbain, as he had published his results earlier. He chose the name lutecium for the new element honoring the Latin name for Paris, Lutetia. In 1949 the spelling was changed to lutetium. In 1909, the priority was finally granted to Urbain and his names were adopted as official ones; however, the name cassiopeium (or later cassiopium) for element 71 proposed by Welsbach was used by many German scientists until the 1950s. Lutetium is not a particularly abundant element, although it is significantly more common than silver in the Earth's crust. It has few specific uses. Lutetium-176 is a relatively abundant (2.6%) radioisotope with a half-life of about 38 billion years, used to determine the age of minerals and meteorites.
Sources: en.wikipedia.org
Hazard research is published: a study demonstrates that exposure to microplastics causes neurobehavioral and immunological changes in mammals (mice), varying by age (1 Aug), a study shows people can't reliably detect speech deepfakes with detection for years-old AI software being at 73% (2 Aug), researchers report an unprecedented accuracy of reading keystrokes from audio of smartphone-recordings or video-chats (7 Aug), a global survey study of climate policy researchers finds these experts substantially doubt the prevailing green growth narrative, "underscor[ing] the importance of considering alternative post-growth perspectives" that include approaches of agrowth and degrowth (7 Aug), a study investigating results from a GBD study finds that while age-standardized number of cardiovascular deaths from PM air pollution have declined during the past three decades, all-age DALYs increased by 31%, reaching ~89 million years in 2019, to which years of potential life lost contributed the most with ~82 million years lost during this year (9 Aug), a study indicates a third of men worldwide are infected with genital human papillomavirus which is relevant to cancer prevention, long-term sequelae and vaccination (16 Aug), a preprint confirms smart bulbs may often be one of the weakest links that can be used to gain access to a nearby person's Wi-Fi network (17 Aug), a GBD study projects cure-less osteoarthritis to affect nearly one billion people by 2050 (21 Aug), a study indicates that all types of straws, including paper straws, except for those made of stainless steel and few exceptions, expose people and their environments to PFAS (24 Aug), a study indicates cannabis is often a source of exposure to the contaminants cadmium and lead (30 Aug), researchers demonstrate Web browser extensions can gather passwords from input fields of many of the largest websites (30 Aug). Promising results of health and medical research are reported: mice- and dogs-tested AOH1996 against cancer growth and for combination with other anti-cancer agents (1 Aug), a mice-tested engineered probiotic against autoimmunity in the brain as in multiple sclerosis (9 Aug), mice-tested engineered bacteria to detect cancer DNA (10 Aug), a review finds that of the compared insecticide-treated nets to prevent malaria, chlorfenapyr-pyrethroid – or PNP combinations – are overall the most effective and address insecticide-resistance (16 Aug), mice-tested clovibactin against antibiotic-resistant bacterial pathogens (22 Aug), two brain implants achieve milestone performances in words per minute and median word error rate (23 Aug), mice-tested phytosterols – or cholesterol-imbalance-correction more broadly – against aging-associated hearing loss (24 Aug), a pig-tested artificial kidney transplant containing a bioreactor containing renal cells for renal replacement therapy (29 Aug), a Raman-based first test for diagnosing ME/CFS and differentiating between severities with potential relevance to long COVID (31 Aug).
=== Absence of benefit === The potential benefit of using essential nutrient dietary supplements to lower the risk of diseases has been refuted by findings of no effect or weak evidence in numerous clinical reviews, such as for HIV, or tuberculosis.
In geometry, Barrow's inequality is an inequality relating the distances between an arbitrary point within a triangle, the vertices of the triangle, and certain points on the sides of the triangle. It is named after David Francis Barrow.
=== Potassium ion channels === Potassium channels come in a variety of forms, are present in most eukaryotic cells, and typically tend to stabilize the cell membrane at the potassium equilibrium potential. As with sodium ions, graded potentials and action potentials are also dependent on potassium channels. While influx of Na+ ions into a neuron induce cellular depolarization, efflux of K+ ions out of a neuron causes a cell to repolarize to resting membrane potential. The activation of potassium ion channels themselves are dependent on the depolarization resulting from Na+ influx during an action potential. As with sodium channels, the potassium channels have their own toxins that block channel protein action. An example of such a toxin is the large cation, tetraethylammonium (TEA), but it is notable that the toxin does not have the same mechanism of action on all potassium channels, given the variety of channel types across species. The presence of potassium channels was first identified in Drosophila melanogaster mutant flies that shook uncontrollably upon anesthesia due to problems in cellular repolarization that led to abnormal neuron and muscle electrophysiology. Potassium channels were first identified by manipulating molecular genetics (of the flies) instead of performing channel protein purification because there were no known high-affinity ligands for potassium channels (such as TEA) at the time of discovery.
== Corporate governance == As of July 2026, Biocon remains chaired by Mazumdar-Shaw. Effective 1 April 2026, Shreehas Tambe was appointed Chief Executive Officer and Managing Director of Biocon Limited—the first CEO of the integrated company following the full integration of Biocon Biologics Limited as a wholly owned subsidiary; Kedar Upadhye was appointed Chief Financial Officer. Tambe succeeded Siddharth Mittal, who resigned effective 31 March 2026 and moved to another leadership role within the Biocon Group. Mittal had led the company since December 2019, when he replaced CEO and Managing Director Arun Chandavarkar. In 2021, Christiane Hamacher resigned as CEO of Biocon Biologics India Limited, following differences with Mazumdar-Shaw. Hamacher had been appointed to that role in March 2019.
Sources: en.wikipedia.org
It targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not act primarily on androgen receptors. This distinction separates it from SARMs.
Rodent studies found dose-dependent tumors in several organs. The sponsor discontinued the program over cancer concerns. Human risk from long-term use remains unknown.
Controlled human endurance trials are lacking. Animal studies show increased exercise capacity under some conditions. Anecdotal reports are not equivalent to clinical evidence.
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.